A phase I/II study of induction therapy with topotecan, mitoxantrone and etoposide in relapsed/refractory acute myeloid leukemia (AML), myeloid blast crisis and high risk myelodysplastic syndromes (MDS).

被引：0
|
作者：
Nand, S [1 ]
Godwin, J [1 ]
White, C [1 ]
Beltran, O [1 ]
Stiff, P [1 ]
机构：
[1] Loyola Univ, Med Ctr, Maywood, IL 60153 USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4649
引用
收藏
页码：214B / 214B
页数：1
相关论文
共 50 条
  • [41] Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) after Multiple Myeloma: Assessment of Risk Factors
    Jonsdottir, Gudbjorg
    Bjorkholm, Magnus
    Turesson, Ingemar
    Hultcrantz, Malin
    Porwit, Anna
    Jethava, Yogesh
    Landgren, Ola
    Kristinsson, Sigurdur Y.
    BLOOD, 2017, 130
  • [42] A Phase I/II Study of Sapacitabine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia
    Desikan, Sai Prasad
    Kantarjian, Hagop
    DiNardo, Courtney D.
    Borthakur, Gautam
    Daver, Naval
    Pemmaraju, Naveen
    Alvarado, Yesid
    Burger, Jan A.
    Linderman, Debra Bull
    Pierce, Sherry A.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    BLOOD, 2021, 138
  • [43] Phase 1 study of LP-108 as monotherapy and in combination with azacitidine in patients with relapsed or refractory myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML).
    Walker, Alison R.
    Bergua Burgues, Juan Miguel
    Montesinos, Pau
    Bixby, Dale
    Guastad Daver, Naval
    Konopleva, Marina
    Patrick Anthony, Stephen
    Tan, Fenlai
    Chen, Yi
    Chen, Yu
    Shen, Yue
    William Burke, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [44] A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
    Navada, Shyamala C.
    Garcia-Manero, Guillermo
    Wilhelm, Francois
    Hearn, Katherine
    Odchimar-Reissig, Rosalie
    Demakos, Erin P.
    Alvarado, Yesid
    Daver, Naval
    DiNardo, Courtney D.
    Konopleva, Marina
    Borthakur, Gautam
    Azarnia, Nozar
    Silverman, Lewis R.
    BLOOD, 2014, 124 (21)
  • [45] Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
    Naval, Daver
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Pemmaraju, Naveen
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Jain, Nitin
    Borthakur, Gautam
    Jabbour, Elias
    Konopleva, Marina
    Cortes, Jorge E.
    Craig, Adam
    Ravandi, Farhad
    BLOOD, 2014, 124 (21)
  • [46] ORAL RIGOSERTIB COMBINED WITH AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROMES (MDS): EFFECTS IN TREATMENT NAIVE AND RELAPSED/REFRACTORY PATIENTS
    Navada, S.
    Garcia-Manero, G.
    Hearn, K.
    Odchimar-Reissig, R.
    Demakos, E.
    Fenaux, P.
    Petrone, M.
    Zbyszewski, P.
    Fruchtman, S.
    Silverman, L.
    HAEMATOLOGICA, 2017, 102 : 183 - 184
  • [47] Phase II evaluation of topotecan and etoposide in relapsed or refractory acute myeloid leukemia - a National Cancer Institute of Canada Clinical Trials Group study
    Crump, M
    Lipton, J
    Bow, E
    Kovacs, M
    Laneuville, P
    Williams, P
    Hedley, D
    Matthews, S
    Eisenhauer, E
    ANNALS OF ONCOLOGY, 1998, 9 : 173 - 173
  • [48] A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Bortezomib for Relapsed/Refractory Acute Myeloid Leukemia
    Advani, Anjali
    Elson, Paul
    Hsi, Eric D.
    Davis, Randall
    Kalaycio, Matt
    Sobecks, Ronald
    Copelan, Edward
    Duong, Hien K.
    Foster, Bethany
    Rush, Mary Lynn
    Farhat, Leslie
    Sekeres, Mikkael A.
    BLOOD, 2012, 120 (21)
  • [49] Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995)
    Greenberg, PL
    Lee, SJ
    Advani, R
    Tallman, MS
    Sikic, BI
    Letendre, L
    Dugan, K
    Lum, B
    Chin, DL
    Dewald, G
    Paietta, E
    Bennett, JM
    Rowe, JM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) : 1078 - 1086
  • [50] A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/Refractory Acute Myeloid Leukemia (AML)
    Advani, Anjali S.
    Cooper, Brenda
    Elson, Paul
    Mukherjee, Sudipto
    Fensterl, Jaime
    Gerds, Aaron T.
    Caimi, Paolo F.
    Tomlinson, Ben K.
    Malek, Ehsan
    Little, Jane A.
    Rush, Mary Lynn
    Bogati, Samjhana
    Parsons, Eric
    Kane, Donna
    Carraway, Hetty E.
    Nazha, Aziz
    Hamilton, Betty K.
    Sobecks, Ronald
    Bevier, Barbara
    Goebel, Christopher
    Zimmerman, Cassie
    Nielsen, Alek D.
    Hirsch, Cassandra M.
    Maciejewski, Jaroslaw P.
    Kalaycio, Matt
    deLima, Marcos
    Jacobberger, James
    Woost, Philip
    Sekeres, Mikkael A.
    BLOOD, 2016, 128 (22)
12345